AQR Capital Management
KPTI icon

AQR Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

AQR Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-815
Closed -$10.1K – 2909
2024
Q3 		$10.1K Sell
815
-49,053
-98% -$610K ﹤0.01% 2748
2024
Q2 		$649K Buy
49,868
+41,480
+495% +$687K ﹤0.01% 1934
2024
Q1 		$190K Sell
8,388
-31,488
-79% -$552K ﹤0.01% 2259
2023
Q4 		$517K Buy
39,876
+6,423
+19% +$86.5K ﹤0.01% 1868
2023
Q3 		$672K Buy
33,453
+22,517
+206% +$505K ﹤0.01% 1747
2023
Q2 		$294K Buy
10,936
+5,568
+104% +$240K ﹤0.01% 1949
2023
Q1 		$313K Buy
5,368
+1,258
+31% +$62.1K ﹤0.01% 1932
2022
Q4 		$210K Sell
4,110
-3,402
-45% -$236K ﹤0.01% 2070
2022
Q3 		$615K Buy
7,512
+6,004
+398% +$448K ﹤0.01% 1700
2022
Q2 		$102K Sell
1,508
-347
-19% -$31.8K ﹤0.01% 2086
2022
Q1 		$205K Buy
+1,855
New +$231K ﹤0.01% 2056
2020
Q4 		– Sell
-5,851
Closed -$1.28M – 2227
2020
Q3 		$1.28M Sell
5,851
-224
-4% -$54.8K ﹤0.01% 1294
2020
Q2 		$1.73M Buy
6,075
+2,094
+53% +$619K ﹤0.01% 1223
2020
Q1 		$1.15M Buy
3,981
+3,208
+415% +$885K ﹤0.01% 1286
2019
Q4 		$222K Buy
+773
New +$168K ﹤0.01% 1984
2019
Q1 		– Sell
-1,706
Closed -$240K – 2194
2018
Q4 		$240K Sell
1,706
-345
-17% -$58.2K ﹤0.01% 2034
2018
Q3 		$524K Buy
2,051
+774
+61% +$214K ﹤0.01% 1944
2018
Q2 		$325K Buy
+1,277
New +$316K ﹤0.01% 2105
2015
Q2 		– Sell
-947
Closed -$435K – 2236
2015
Q1 		$435K Buy
947
+140
+17% +$60.4K ﹤0.01% 1743
2014
Q4 		$453K Buy
+807
New +$458K ﹤0.01% 2013

Other funds holding KPTI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

AQR Capital Management's KPTI Position: Q4 2024 in Review

AQR Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2024, closing a stake of 815 shares — an estimated $10.1K sold.

AQR Capital Management first reported a position in KPTI in Q4 2014 and held it in 20 quarters. The position peaked at $1.73M in Q2 2020. 87 funds tracked by Wall St. Rank hold KPTI as of Q4 2024.

  • AQR Capital Management reported no remaining Karyopharm Therapeutics position as of Q4 2024 after selling out during the quarter.
  • AQR Capital Management sold 815 Karyopharm Therapeutics shares in Q4 2024, an estimated $10.1K.
  • AQR Capital Management first reported a position in Karyopharm Therapeutics in Q4 2014 and held it in 20 quarters.
  • AQR Capital Management's Karyopharm Therapeutics position peaked at $1.73M in Q2 2020.
  • 87 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2024.

Based on AQR Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.